MAOB and central nervous system cancer: However, in Supplementary Figure 1 we show representative images of Sp3 levels in glioma tumors, without hematoxylin, that we have divided into two populations; Supplementary Figure 1A, where Sp3 immunohistochemical labeling is shown in 16 GBM, arranged in order of increasing MAOB levels and Supplementary Figure 1B, where Sp3 labeling is shown in 4 GBM, 7 astrocytic glioma and a brain section control, again arranged with respect to increasing MAOB levels.